Stemina Launches Cardiotoxicity Assay, Presents Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2018
Feb 20, 2018Stemina Launches Cardiotoxicity Assay, Presents Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2018 The Stemina team will attend the Society of Toxicology’s Annual Meeting and ToxExpo in San Antonio, Texas from March 11-15, 2018. We are excited to share information about our new cardiotoxicity assay, Cardio quickPredict, now commercially-available for the first time.
NeuroPointDX Announces Validation of First-Generation Autism Diagnostic Panel
Jan 18, 2018NeuroPointDX, the neurodevelopmental disorders division of Stemina Biomarker Discovery, has validated 12 metabolic subtypes of autism spectrum disorder. The diagnostic blood test for ASD will be available later this year. CEO Elizabeth Donley says, “This is a historic moment, not just for Stemina and NeuroPointDX, but for our knowledge and understanding of autism.” Read the
Stemina to Present a Poster at American College of Toxicology Annual Meeting
Oct 25, 2017Jessica Palmer, Stemina’s Associate Director of Toxicology, will present a poster at the American College of Toxicology’s 38th Annual Meeting, held November 5-8, 2017 in Palm Springs, California. Anyone interested in cardiotoxicity assays is encouraged to attend. Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Stem Cell-Derived Cardiomyocytes